Mostrar el registro sencillo del documento

dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.contributor.advisorZúñiga Pavia, Sergio
dc.contributor.authorFigueroa Bohórquez, David Mauricio
dc.date.accessioned2021-02-03T23:40:38Z
dc.date.available2021-02-03T23:40:38Z
dc.date.issued2021-01-25
dc.identifier.citationFigueroa Bohórquez, D. M. (2021). Factores pronósticos y supervivencia en pacientes con cáncer de tiroides: supresión de tirotropina y recaída de la enfermedad [Tesis de especialidad, Universidad Nacional de Colombia]. Repositorio Institucional.
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/79066
dc.description.abstractIntroduction: Papillary thyroid cancer is the most common endocrine tumor worldwide. It is necessary to know in our population the risk factors that increase the likelihood of disease relapse after treatment, and to estimate the efficacy of other treatment strategies, such as TSH suppression. Materials and methods: Ambispective cohort study, which included patients undergoing surgery for well-differentiated thyroid cancer and subsequently followed for a period of 3 and a half years. Bivariate analyzes were performed between the different study variables and the outcome of relapse, then a multivariate linear regression model was performed. Results: 816 patients with differentiated thyroid cancer were included. 85.7% of the patients were women, papillary histology was found in 98.8% of the cases. In 62.25% of patients, some type of lymph node involvement was confirmed. It was demonstrated in the multivariate logistic regression analysis that the isthmic location of the tumor, the lymphatic invasion, the extrathyroid extension and the presence of lymph node involvement in the initial surgery are related to a higher probability of relapse. On the other hand, it was not found that TSH suppression increases recurrence either in general, or differentiating by subgroups of risk of relapse. Discussion: We were able to identify the main risk factors in our population, which are related to disease relapse. On the other hand, these results increase the evidence that support that the TSH suppression does not impact in the relapse of the disease.
dc.description.abstractIntroducción El cáncer papilar de tiroides es el tumor endocrino más frecuente a nivel mundial. Es necesario conocer en nuestro medio los factores de riesgo que aumentan la probabilidad de recaída de la enfermedad, y estimar la eficacia de otras medidas actualmente utilizadas, como la supresión de la TSH. Materiales y métodos: Estudio de cohorte ambispectivo, que incluyó pacientes llevados a cirugía por cáncer de tiroides bien diferenciado y seguidos posteriormente durante un periodo de 3 años y medio. Se realizaron análisis bivariados entre las diferentes variables estudiadas y el desenlace de recaída, posteriormente se realizó un modelo de regresión lineal multivariado. Resultados: Se incluyeron 816 pacientes con cáncer diferenciado de tiroides. El 85,7% de los pacientes fueron mujeres, documentándose la histología papilar en el 98,8% de los casos. En el 62,25% de pacientes se confirmó algún tipo de compromiso ganglionar. En el análisis de regresión logística multivariado se demostró que la localización ístmica del tumor, la invasión linfática, la extensión extratiroidea y la presencia de compromiso ganglionar en la cirugía inicial, están relacionados con mayor probabilidad de recaída. Por otro lado, no se encontró relación entre el estatus de supresión de la TSH y el riesgo de recaída. Discusión: Se lograron identificar a los principales factores de riesgo en nuestra población, que se relacionan con recaída de la enfermedad. Por otro lado, aumenta la evidencia que soporta que la supresión de TSH no impacta en riesgo de recaída.
dc.format.extent46
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rightsDerechos reservados - Universidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610 - Medicina y salud
dc.titleFactores pronósticos y supervivencia en pacientes con cáncer de tiroides: supresión de tirotropina y recaída de la enfermedad
dc.typeOtro
dc.rights.spaAcceso abierto
dc.description.additionalLinea de investigación en cirugía de cabeza y cuello.
dc.type.driverinfo:eu-repo/semantics/other
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Cirugía General
dc.description.degreelevelEspecialidades Médicas
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.referencesLaetitia G, Sven S, Fabrice J. Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses. Cells 2020;9(4):830.
dc.relation.referencesFerlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-1403.
dc.relation.referencesPardo C, Cendales R. Incidencia, mortalidad y prevalencia de cáncer en Colombia, 2007-2011. Primera edición. Bogotá, D.C: Instituto Nacional de Cancerología; 2015. Disponible en: http://www.cancer.gov.co/publicaciones?idpadre=1&idcategoria=59
dc.relation.referencesHaugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133
dc.relation.referencesLiu FH, Kuo SF, Hsueh C, Chao TC, Lin JD. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. J Surg Oncol. 2015; 112(2):149–54.
dc.relation.referencesIto Y, Kudo T, Kobayashi K, Miya A, Ichihara K, Miyauchi A. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with average 10-year follow-up. World J Surg. 2012; 36(6):1274–8.
dc.relation.referencesMaria F Bates, Marcos R Lamas, Reese W Randle, Kristin L Long, Susan C Pitt, David F Schneider, et al. Back so soon? – Is early recurrence of Papillary Thyroid Cancer really just persistent disease?, Surgery. 2018 January ; 163(1): 118–123.
dc.relation.referencesJackson BS. Controversy regarding when clinically suspicious thyroid nodules should be subjected to surgery: Review of current guidelines. Medicine (Baltimore). 2018;97(50):13634
dc.relation.referencesJonklaas J, Sarlis N, Litofsky D, Ain K, Bigos T, Brierley J, et, al. Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial Therapy. Thyroid. 2006;16(12):1229-42.
dc.relation.referencesHegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764
dc.relation.referencesBelfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh). 1989; 121:197.
dc.relation.referencesGaravito G. Factores pronósticos para la recaída en pacientes con cáncer papilar de tiroides. Rev Colomb Cancerol. 2005; 9(2):21-30.
dc.relation.referencesMitchell A, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130(2):150–60.
dc.relation.referencesHaddad R, Nasr C, Bischoff L, Busaidy N, Byrd D, Callender G. Thyroid Carcinoma, Version 2.2018. Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2018;16(12):1429–1440
dc.relation.referencesFlynn RW, Bonellie SR, Jung RT, Macdonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(1):186-93
dc.relation.referencesGussekloo J, van ExelE,de Craen AJ,Meinders AE, FrolichM, Westendorp RG.Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591–9
dc.relation.referencesCooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214
dc.relation.referencesRico-Morlán FJL, Hernández-Cuéllar A, Martínez-Macías R, Barra-Martínez R, Santiago Vázquez RY. Serum levels of tyroglobulin like predictor of malignancy in patients with tyroid nodule. GAMO.2009; 8(2):54-61
dc.relation.referencesNascimento C, Borget I , Troalen F , et al. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur J Endocrinol .2013;169:689–693 .
dc.relation.referencesKuo JH, McManus C, Graves CE, Madani A, Khokhar MT, Huang B, Lee JA. Updates in the management of thyroid nodules. Curr Probl Surg. 2019;56(3):103-127
dc.relation.referencesPark S, Jeon MJ, Oh HS, Lee YM, Sung TY, Han M, Han JM, Kim TY, Chung KW, Kim WB, Shong YK, Kim WG. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer. Thyroid. 2018;28(8):997-1003.
dc.relation.referencesDiessl S, Holzberger B, Mädert U, Grelle I, Smit J, BuckA, et al. Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clinical Endocrinology. 2012;76,586–592
dc.relation.referencesPujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab. 1996;81(12):4318-23
dc.relation.referencesCooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR III. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737–744
dc.relation.referencesMcGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med. 2002;34:554–564
dc.relation.referencesBiondi B, Cooper DSBenefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid. 2010;20:135–146
dc.relation.referencesvan den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, . physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90:6403–6409.
dc.relation.referencesDe Melo TG, da Assumpção LV, Santos Ade O, Zantut-Wittmann DE. Low BMI and low TSH value as risk factors related to lower bone mineral density in postmenospausal women under levothyroxine therapy for differentiated thyroid carcinoma. Thyroid Res. 2015;8:7
dc.relation.referencesSugitani I, Fujimoto Y. Does Postoperative Thyrotropin Suppression Therapy Truly Decrease Recurrence in Papillary Thyroid Carcinoma? A Randomized Controlled Trial. J Clin Endocrinol Metab. 2010;95(10):4576–83
dc.relation.referencesKlubo-Gwiezdzinska J, Auh S, Gershengorn M, Daley B, Bikas A, Burman K, Et al. Association of Thyrotropin Suppression With Survival Outcomesin Patients With Intermediate- and High-Risk Differentiated Thyroid Cancer. JAMA Netw Open. 2019;2(2).e187754.
dc.relation.referencesZetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010;17:3287–93.
dc.relation.referencesWang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(11):3477-3483.
dc.relation.referencesBiondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149-163.
dc.relation.referencesKlein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol. 2013;31(32):4046-53.
dc.relation.referencesKim HJ, Sohn SY, Jang HW, Kim SW, Chung JH. Multifocality, but not bilaterality, is a predictor of disease recurrence/persistence of papillary thyroid carcinoma. World J Surg. 2013;37(2):376-384.
dc.relation.referencesLin JD, Chao TC, Hsueh C, Kuo SF. High recurrent rate of multicentric papillary thyroid carcinoma. Ann Surg Oncol. 2009;16(9):2609-2616.
dc.relation.referencesWang, W., Su, X., He, K., Wang, Y., Wang, H., Wang, H., Zhao, Y., Zhao, W., Zarnegar, R., Fahey, T., Teng, X. and Teng, L. Comparison of the clinicopathologic features and prognosis of bilateral versus unilateral multifocal papillary thyroid cancer: An updated study with more than 2000 consecutive patients. Cancer. 2015;122(2):198-206.
dc.relation.referencesWang F, Yu X, Shen X, et al. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2017;102(9):3241- 3250
dc.relation.referencesRandolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144-1152.
dc.relation.referencesLeboulleux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723-5729.
dc.relation.referencesLango M, Flieder D, Arrangoiz R, et al. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression. Thyroid. 2013;23(9):1099-1105.
dc.relation.referencesLee J, Song Y, Soh EY. Prognostic significance of the number of metastatic lymph nodes to stratify the risk of recurrence. World J Surg. 2014;38(4):858-862.
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.proposalCáncer papilar tiroideo
dc.subject.proposalThyroidectomy
dc.subject.proposalLymphatic metastasis
dc.subject.proposalMetástasis linfática
dc.subject.proposalNeck dissection
dc.subject.proposalTiroidectomía
dc.subject.proposalDisección del cuello
dc.subject.proposalThyroid cancer
dc.subject.proposalPapillary
dc.type.coarhttp://purl.org/coar/resource_type/c_1843
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2


Archivos en el documento

Thumbnail
Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento

Atribución-NoComercial-SinDerivadas 4.0 InternacionalEsta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.Este documento ha sido depositado por parte de el(los) autor(es) bajo la siguiente constancia de depósito